1-10 of 10
Jun Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B008: Machine-learning enabled quantification of colocalized multiplex IHC signals with spectral overlap

Waleed Tahir, Yibo Zhang, Jun Zhang, Jacqueline Brosnan-Cashman, Robert Egger, Justin Lee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B008.
https://doi.org/10.1158/1535-7163.TARG-23-B008
Published: 01 December 2023
View article titled, Abstract B008: Machine-learning enabled quantification of colocalized multiplex IHC signals with spectral overlap
Journal Articles

Abstract LB_A10: Efficacy of ATR inhibitor berzosertib plus topotecan or topotecan alone in patients with relapsed small cell lung cancer: A randomized clinical trial

Nobuyuki Takahashi, Zhonglin Hao, Liza C Villaruz, Jun Zhang, Jimmy Ruiz, W. Jeffrey Petty, Hirva Mamdani, Jonathan W Riess, Jorge Nieva, Jose M Pachecho, Alexander D Fuld, Elaine Shum, Aman Chauhan, Samantha Nichols, Hirity Shimellis, Jessie McGlone, Linda Sciuto, Danielle Pinkiert, Chante Graham, Meenakshi Shelat, Robbie Kattappuram, Melissa Abel, Brett Schroeder, Deep Upadhyay, Manan Krishnamurthy, Ajit Kumar Sharma, Rajesh Kumar, Justin Malin, Christopher W Schultz, Shubhank Goyal, Christophe E Redon, Yves Pommier, Mirit I Aladjem, Steven D Gore, Seth M Steinberg, Rasa Vilimas, Parth Desai, Anish Thomas
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): LB_A10.
https://doi.org/10.1158/1535-7163.TARG-23-LB_A10
Published: 01 December 2023
View article titled, Abstract LB_A10: Efficacy of ATR inhibitor berzosertib plus topotecan or topotecan alone in patients with relapsed small cell lung cancer: A randomized clinical trial
Journal Articles

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers

Neil A. O'Brien, Martina S.J. McDermott, Jun Zhang, Ke Wei Gong, Ming Lu, Benjamin Hoffstrom, Tong Luo, Raul Ayala, Kevin Chau, Min Liang, Athena M. Madrid, Timothy R. Donahue, John A. Glaspy, Leonard Presta, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12): 1365–1375.
https://doi.org/10.1158/1535-7163.MCT-23-0353
Published: 01 December 2023
View article titled, Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers
Open the PDF for Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody–Drug Conjugate for Treatment of CLDN18.2-Positive Cancers in another window
Includes: Supplementary data
Journal Articles

Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies

Neil A. O'Brien, Holly K.T. Huang, Martina S.J. McDermott, Athena M. Madrid, Tong Luo, Raul Ayala, Shawnt Issakhanian, Ke Wei Gong, Ming Lu, Jun Zhang, Dennis J. Slamon
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (5): 751–761.
https://doi.org/10.1158/1535-7163.MCT-21-0847
Published: 04 May 2022
View article titled, Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies
Open the PDF for Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer–Targeted Therapies in another window
Includes: Supplementary data
Journal Articles

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors

Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, Sylvie Rottey, Simon A.J. Rule, David Cunningham, Frederic Peyrade, Christophe Fruchart, Hendrik-Tobias Arkenau, Isabelle Genvresse, Li Liu, Karl Köchert, Kui Shen, Christoph Kneip, Carol E. Peña, Joachim Grevel, Jun Zhang, Galia Cisternas, Susanne Reschke, Camille Granvil, Ahmad Awada
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2020) 19 (2): 468–478.
https://doi.org/10.1158/1535-7163.MCT-19-0466
Published: 06 February 2020
View article titled, On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors
Open the PDF for On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract A095: Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer

Raffit Hassan, Ding Wang, John Wrangle, Anish Thomas, Angus Byars, Lianne Asschert, Rolando Atienza, Prabhu Rajagopalan, Annette Walter, Jun Zhang, Nenad Sarapa, Hedy Kindler
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A095.
https://doi.org/10.1158/1535-7163.TARG-17-A095
Published: 01 January 2018
View article titled, Abstract A095: Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer
Journal Articles

Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α

Tian-Yu Cai, Xiao-Wen Liu, Hong Zhu, Ji Cao, Jun Zhang, Ling Ding, Jian-Shu Lou, Qiao-Jun He, Bo Yang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (3): 630–642.
https://doi.org/10.1158/1535-7163.MCT-13-0490
Published: 09 March 2014
View article titled, Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α
Open the PDF for Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1α in another window
Includes: Supplementary data
Journal Articles

A Novel Plant Homeodomain Finger 10–Mediated Antiapoptotic Mechanism Involving Repression of Caspase-3 in Gastric Cancer Cells

Min Wei, Bingya Liu, Liping Su, Jianfang Li, Jun Zhang, Yingyan Yu, Min Yan, Zhongyin Yang, Xuehua Chen, Jiayun Liu, Xin Lv, Hui Nie, Qing Zhang, Zhong Zheng, Beiqin Yu, Jun Ji, Jianian Zhang, Zhenggang Zhu, Qinlong Gu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (6): 1764–1774.
https://doi.org/10.1158/1535-7163.MCT-09-1162
Published: 09 June 2010
View article titled, A Novel Plant Homeodomain Finger 10–Mediated Antiapoptotic Mechanism Involving Repression of Caspase-3 in Gastric Cancer Cells
Open the PDF for A Novel Plant Homeodomain Finger 10–Mediated Antiapoptotic Mechanism Involving Repression of Caspase-3 in Gastric Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Pharmacokinetic comparison of multiple receptor tyrosine kinase inhibitor ABT-869 in Asian and Caucasian populations

Neeraj Gupta, Boon-Cher Goh, Ross Soo, Chiung Ing Wong, Jun Zhang, Sari Enschede, Joyce Steinberg, Rod Humerickhouse
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C148.
Published: 01 November 2007
View article titled, Pharmacokinetic comparison of multiple receptor tyrosine kinase inhibitor ABT-869 in Asian and Caucasian populations
Journal Articles

Relative bioavailability study of multiple receptor tyrosine kinase inhibitor ABT- 869 for comparison of oral solution and tablet formulation

Neeraj Gupta, Boon-Cher Goh, Ross Soo, Chiung Ing Wong, Jun Zhang, Bernd Liepold, Joerg Rosenberg, Martin Knobloch, Joyce Steinberg, Rod Humerickhouse
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C149.
Published: 01 November 2007
View article titled, Relative bioavailability study of multiple receptor tyrosine kinase inhibitor ABT- 869 for comparison of oral solution and tablet formulation